<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Gastric Cancer PDX Models

With many new agents under development, including targeted therapies for gastric cancer, there is a need for predictive research models such as patient-derived xenografts (PDX) for preclinical evaluation. PDX models are proven to be highly predictive models for preclinical drug assessment. The Crown Bioscience collection contains over 100 well characterized gastric cancer PDX models, including EGFR amplified models and cachexic models. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL NUMBER CANCER TYPE CANCER SUBTYPE DESCRIPTION # per page
GA0006 Gastric Cancer ADC Adenocarcinoma of gastric cardia of lesser curvature side, ulcerative type, carcinoma in situ, moderately-poorly differentiated, tumor mass: 6.5cm x 5cm x 2.5cm. CLICK TO VIEW
GA0019 Gastric Cancer ADC Adenocarcinoma of gastic cardia, infiltrative ulcerative type, moderately differentiated, tumor mass: 5cm x 4.5cm x 2.5cm, infiltrating into adipose tissue external serosa and nerve plexus in gastric wall. Malignant cells were observed in lesser curvature LN and cardial LN. CLICK TO VIEW
GA0022 Gastric Cancer ADC Adenocarcinoma of gastic cardia, ulcerative type, moderately-poorly differentiated, tumor mass: 5cm x 4cm x 2.5cm, infiltrating gastric wall to serosa. No visible malignant cells adjacent to both stump. Regional LN: left gastric LN (5/9), LN of inferior parapulmonary vein (0/6). CLICK TO VIEW
GA0023 Gastric Cancer ADC Adenocarcinoma, ulcerative type, poorly differenciated. CLICK TO VIEW
GA0025 Gastric Cancer Signet-ring cell carcinoma Signet-ring cell carcinoma of gastric greater curvature, parts are mucinous adenocarcinoma, protruded type, tumor mass: 3.5cm x 3.5cm x 2cm, infiltrating into gastric wall. Regional LN: LN surround celiac trunk (1/1). IHC results: HER-1(-), HER-2(-), p53(-), p170(-), Ki-67(+ 25~50%), VEGF(+), TopIIa(+<25%), p16(-). CLICK TO VIEW
GA0031 Gastric Cancer ADC Adenocarcinoma of stomach, ulcerative type, moderately-poorly differentiated, tumor mass: 6cm x 4cm x 1cm, infiltrating into serosa. No visible malignant cells adjacent to both stump. Regional LN: LN of lesser curvature (2/5), LN of greater curvature (0/2). CLICK TO VIEW
GA0033 Gastric Cancer ADC Adenocarcinoma of gastric cardia, ulcerative type, poorly differentiated, tumor mass: 9cm x 6cm x 1.5cm, infiltrating into serosa, and accompanied with necrosis and a few lymphocytes deposition. No visible malignant cells adjacent to both stump. Regional LN: cardial LN (0/5), left gastric LN (0/7). CLICK TO VIEW
GA0037 Gastric Cancer ADC Adenocarcinoma of gastric cardia, ulcerative type,poorly differentiated, tumor mass: 4cm x 4cm x 2.5cm, infiltrating into serosa. No visible malignant cells adjacent to both stump. Regional LN: LN of lesser curvature (0/9). CLICK TO VIEW
GA0044 Gastric Cancer ADC Metastatic adenocarcinoma derived from liver, moderately-poorly differenciated. The patient had been done gastric cancer surgery 2 years ago. CLICK TO VIEW
GA0046 Gastric Cancer ADC Adenocarcinoma derived from juncture of stomach and esophagus in lesser gastric curvature, protrude, ulcerative type, poorly differentiated, tumor mass: 6cm x 5cm x 1.5cm. Malignant cells infiltrating into gastric wall and esophagus. Regional LN: LN of lesser curvature (3/14). IHC results: HER-1(+), HER-2(-), p53(+ 25~50%), p170(-),Ki-67(+, 25-50%), VEGF(++), Top-IIa(+ about 10%), p16(-). CLICK TO VIEW
GA0055 Gastric Cancer ADC Clear cell adenocarcinoma of anterior wall of gastric antrum, ulcerative type, moderately differentiated. Regional LN: LN of lesser curvature (2/6), LN of greater curvature (2/6), LN of the eighth group (1/1). IHC results: HER-1(-), HER-2(+), p53(+ 25~50%), p170(focus +), Ki-67(+<10%), VEGF(++), Top-IIa(+<1%), p16(++). CLICK TO VIEW
GA0060 Gastric Cancer ADC Adenocarcinoma of gastric antrum, ulcerative type, moderately-poorly differentiated, tumor mass: 4cm x 6cm x 2cm, invaded adipose tissue external serosa, no visible malignant cells adjacent to both stump. Regional LN: LN of greater curvature (7/7), LN of lesser curvature (6/6). CLICK TO VIEW
GA0074 Gastric Cancer ADC Adenocarcinoma of gastric cardia, ulcerative type, poorly differentiated, tumor mass: 5cm x 4cm x 0.8cm, invading deep muscular layer and massive gastric wall. No malignant cells adjacent to both stump. Regional LN: LN of lesser curvature (1/3), cardial LN (0/5). CLICK TO VIEW
GA0075 Gastric Cancer ADC Adenocarcinoma of cardia and fundus of stomach, infiltrative ulcerative type, moderately-poorly differentiated, tumor mass: 6.5cm x 5cm x 1.5cm, infiltrating into serosa. No malignant cells adjacent to both stump. Regional LN: LN of lesser curvature(1/6), cardial LN(0/4), LN of greater curvature (0/4), LN of para-inferior pulmonary vein (0/3). CLICK TO VIEW
GA0080 Gastric Cancer ADC 1. Adenocarcinoma of gastric cardia, invasive type, moderately-poorly differentiated, tumor mass: 8cm x 6cm x 1.5cm, infiltrating into serosa. No visible malignant cells adjacent to both stump. Regional LN: cardial LN (1/5), left gastric LN (2/2). 2. Hepatitis, type B CLICK TO VIEW
GA0087 Gastric Cancer NEC, carcinoid Carcinoid of gastric cardia, ulcerative type, tumor mass: 7cm x 5.5cm x 1.5cm, invading into serosa, no malignant cells adjacent to both stump and omentum majus. Regional LN: LN of lesser curvature (3/4), inferior esophageal LN (0/1). IHC results: Syn(-), CgA(+), NSE(-). CLICK TO VIEW
GA0091 Gastric Cancer NEC, carcinoid Carcinoid of gastric cardia, ulcerative type, tumor mass: 7cm x 5.5cm x 1.5cm, invading into serosa, no malignant cells adjacent to both stump and omentum majus. Regional LN: LN of lesser curvature (3/4), inferior esophageal LN (0/1). IHC results: Syn(-), CgA(+), NSE(-). CLICK TO VIEW
GA0095 Gastric Cancer ADC Adenocarcinoma of gastic cardia, ulcerative type, poorly differentiated, tumor mass: 6cm x 5cm x 2.5cm, invaded nerve plexus of gastric wall and adipose tissue external serosa. No visible malignant cells adjacent to superior stump. Severe acinar hyperplasia in inferior stump. Regional LN: lymphatic fusion were observed in lesser curvature and cardia. Metastatic tumor cell presented in the LN. CLICK TO VIEW
GA0098 Gastric Cancer ADC Adenocarcinoma of gastric cardia, invasive, ulcerative type, moderately differentiated, tumor mass: 5cm x 4.5cm x 2cm, infiltrating into serosa and squamous epithelium of inferior esophagus. No visible malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/1), cardial LN (0/5). Lymphatic fusion were observed in lesser curvature. Metastatic tumor cell presented in the LN. CLICK TO VIEW
GA0103 Gastric Cancer ADC moderately-poorly differentiated adenocarcinoma of gastric cardia (ulcerative) CLICK TO VIEW
GA0114 Gastric Cancer ADC Gastric adenocarcinoma cancer patient-derived xenograft (PDX) model GA0114. CLICK TO VIEW
GA0119 Gastric Cancer ADC, mucinous Adenocarcinoma of gastric cardia with mucinous adenocarcinoma and some signet-ring cell carcinoma, ulcerative type,poorly differentiated, tumor mass: 6.5cm x 7cm x 2cm, infiltrating into serosa and nerve plexus. Malignant cells adjacent to inferior stump. Regional LN: LN of lesser curvature (6/6), left gastric LN (5/6), inferior pyloric LN (1/1). CLICK TO VIEW
GA0138 Gastric Cancer ADC Adenocarcinoma of stomach, invasive, ulcerative type, poorly differentiated, tumor mass: 11cm x 9cm x 3cm, infiltrating into deep muscular layer, no visible malignant cells adjacent to both stump. Regional LN: LN of lesser curvature (1/5). CLICK TO VIEW
GA0139 Gastric Cancer ADC Adenocarcinoma of gastric cardia with papillary adenocarcinoma, ulcerative type, moderately differentiated, tumor mass: 6.5cm x 7cm x 1cm, infiltrating into adipose tissue external serosa. No malignant cells adjacent to both stump. Regional LN: LN of lesser curvature (0/11), paraesophageal LN (0/4). CLICK TO VIEW
GA0151 Gastric Cancer ADC Adenocarcinoma of gastric antrum, ulcerative type, moderately-poorly differentiated, tumor mass: 3cm x 2.5cm x 1cm, infiltrating into serosa. No visible malignant cells adjacent to both stump and omentum majus. Regional LN: LN of lesser curvature (1/4). CLICK TO VIEW
GA0152 Gastric Cancer ADC Poorly differentiated adenocarcinoma CLICK TO VIEW
GA0318 Gastric Cancer ADC Adenocarcinoma of duodenal papilla. Infiltrating into pancreas. No visible malignant cells adjacent to both of stump and choledochal stump. Regional LN: LN of the twelfth group (0/1) CLICK TO VIEW
GA0429 Gastric Cancer ADC Metastatic tubular adenocarcinoma in brain, consider originate from gastrointestinal tract.IHC results: CK(++), CEA(+), CK8/18(++), Ki67(++), CK7(+/-), PCNA(++), CK18(++), CK20(+), EMA(+). CLICK TO VIEW
GA1224 Gastric Cancer ADC Poorly differentiated adenocarcinoma of gastric cardia with hepatic metastases. The neoplastic cells are cubical and polygon cells with nuclear atypia. The tumor forms tubular and nest structures and has an infiltrative growth pattern. Regional LN: LN of lesser curvature (3/12), LN of greater curvature (0/4). CLICK TO VIEW
GA13732 Gastric Cancer NA Gastroesophageal Carcinoma CLICK TO VIEW
GA13739 Gastric Cancer NA NA CLICK TO VIEW
GA13741 Gastric Cancer ADC N/A CLICK TO VIEW
GA13744 Gastric Cancer NA Metastatic Gastric Carcinoma CLICK TO VIEW
GA13748 Gastric Cancer NA Gastric Cancer CLICK TO VIEW
GA13750 Gastric Cancer N/A N/A CLICK TO VIEW
GA13756 Gastric Cancer NA Gastic Carcinoma CLICK TO VIEW
GA13760 Gastric Cancer NA Gastric Carcinoma CLICK TO VIEW
GA13761 Gastric Cancer NA Gastric Cancer CLICK TO VIEW
GA13762 Gastric Cancer NA Stomach Carcinoma, KRUKENBERG TUMOR CLICK TO VIEW
GA13765 Gastric Cancer NA Stomach Carcinoma CLICK TO VIEW
GA13766 Gastric Cancer NA Stomach Carcinoma, adenocarcinoma of stomach. CLICK TO VIEW
GA13775 Gastric Cancer NA NA CLICK TO VIEW
GA13777 Gastric Cancer ADC Stomach Carcinoma. Adenocarcinoma. CLICK TO VIEW
GA13782 Gastric Cancer NA Gastro-esophageal carcinoma, signet ring cell adenocarcinoma. CLICK TO VIEW
GA13801 Gastric Cancer ADC N/A CLICK TO VIEW
GA13804 Gastric Cancer NA Gastric ring cancer CLICK TO VIEW
GA13806 Gastric Cancer ADC N/A CLICK TO VIEW
GA2101 Gastric Cancer ADC Moderately differentiated adenocarcinoma of gastric antrum, in lesser curvature, ulcerative type, tumor mass: 3 x 3cm. The tumor invade through gastric wall. Caner embolus may be seen in vessel. Regional LN: NO.1 (black) LN (0/2), NO.1 LN (0/2), NO.3 LN (black) (0/5), NO.3 LN (1/1), NO.4SB LN (0/0), NO.4sd LN (0/1), NO.5 LN (0/2), NO.6 LN (0/4), NO.8 LN (0/8), NO.12A (0/2), NO.14V (0/0). IHC results: CD34(blood vessel +), CD44(focal +), cMet(-), D2-40(vessel +), EGFR(-), HER2(1+), Ki-67(+50~75%), MMP7(+), P170(+), P27(+<25%), P53(-), TOPOII(+<5%). CLICK TO VIEW
GA2103 Gastric Cancer ADC Adenocarcinoma of gastric cardia with mucinous adenocarcinoma, ulcerative type, moderately differentiated, tumor mass: 8cm x 7cm, infiltrating through gastric wall. No malignant cells adjacent to stump. Regional LN: left cardial LN (1/1), LN of lesser curvature (4/6), right cardial LN (0/4), inferior pyloric LN (0/5), common hepatic arterial LN (0/4). IHC results; CD44(+), Cmet(+), EGFR(-), HER2(-), Ki-67(+25-50%), MMP7(+), P170(+), P27(+50-75%), P53(+>75%), TOPOII(+25-50%) CLICK TO VIEW
GA2109 Gastric Cancer ADC Moderately differentiated adenocarcinoma of juncture of stomach and esophagus, ulcerative type, tumor mass: 5.0 x 4.5cm. The tumor invade through gastric wall. Regional LN: LN of lesser curvature (0/12), LN of greater curvature (0/2), NO.7,8 LN (0/4). IHC results: CD44(+), cMet(+), EGFR(-), HER2(1+), Ki-67(+ 25%), MMP7(+), P170(+), P27(+ 25%), P53(-), TOPOII(+ 25%). CLICK TO VIEW
GA2117 Gastric Cancer ADC Metastatic mucinous adenocarcinoma from tissue surrounding navel CLICK TO VIEW
GA2140 Gastric Cancer ADC Gastric adenocarcinoma,poorly differentiated CLICK TO VIEW
GA2148 Gastric Cancer ADC Poorly differentiated adenocarcinoma of gastric antrum and lesser curvature, ulcerative type, tumor mass: 2.0 x 1.5cm. The tumor invade gastric serosa and nervus. Regional LN: NO.3 LN (1/4), NO.1 LN (0/1), NO.4D LN (0/2), NO.7 LN (0/5), NO.8 LN (0/6), NO.8P LN (0/5), NO.11P LN ( 0/2), NO.12 LN (0/1). IHC results: CD44(+), cMet(+), EGFR(+ 75%), HER2(-), Ki-67(+ 75%), MMP7(-), P170(-), P27(+ 75%), P53(+ 25%), TOPOII(+ 25%). CLICK TO VIEW
GA2157 Gastric Cancer ADC Moderately-poorly differentiated adenocarcinoma of gastric antrum, with part of signet ring cell carcinoma, ulcerative type, tumor mass: 5.0 x 5.0cm. The tumor invade through gastric wall to serosa of pancreas and gallbladder. Regional LN: NO.1 LN (6/8), NO.3 LN (14/17), NO.5 LN (2/2), NO.6 LN (2/2), NO.7 LN (4/6), NO.4D LN (10/11), NO.8 LN (1/2). IHC results: CD44(+), cMet(weak +), EGFR(+), HER2(3+), Ki-67(+50-75%), MMP7(-), P170(-), P27(+50-75%), P53(+>75%), TOPOII(-). CLICK TO VIEW
GA2180 Gastric Cancer NA NA CLICK TO VIEW
GA2192 Gastric Cancer ADC Poorly differentiated adenocarcinoma of gastric cardia and fundus, ulcerative type. The tumor invade through gastric wall. CLICK TO VIEW
GA2228 Gastric Cancer SCC N/A CLICK TO VIEW
GA2253 Gastric Cancer Adenocarcinoma NA CLICK TO VIEW
GA2254 Gastric Cancer ADC and Signet-ring cell carcinoma Moderately to poorly differentiated adenocarcinoma with signet ring cell carcinoma CLICK TO VIEW
GA2256 Gastric Cancer N/A N/A CLICK TO VIEW
GA2257 Gastric Cancer NA Ovarian: signet-ring cell carcinoma and poorly differentiated adenocarcinoma, considered gastric cancer on basis of medical history. CLICK TO VIEW
GA2269 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma of antrum of stomach, tumor size: 5.5x5cm, infiltrating through gastric wall. Six of sixteen lymph nodes involved by metastatic carcinoma. CLICK TO VIEW
GA2278 Gastric Cancer ADC No dianosis info from hospital. CLICK TO VIEW
GA2315 Gastric Cancer Mucinous adenocarcinoma NA CLICK TO VIEW
GA2419 Gastric Cancer ADC NA for clinical diagnosis info. CLICK TO VIEW
GA2420 Gastric Cancer ADC NA for clinical diagnosis info. CLICK TO VIEW
GA2421 Gastric Cancer ADC NA for clinical diagnosis info. CLICK TO VIEW
GA2434 Gastric Cancer ADC NA for clinical diagnosis info. CLICK TO VIEW
GA2435 Gastric Cancer ADC NA for clinical diagnosis info. CLICK TO VIEW
GA3049 Gastric Cancer ADC Moderately differentiated adenocarcinoma of gastric antrum. The tumor forms irregular glandular or cribriform structures and has an infiltrative growth pattern. Regional LN: LN of proximal lesser curvature (0/9), LN of distal lesser curvature (0/7), LN of proximal greater curvature (1/3), LN of distal greater curvature (4/7), common hepatic arterial LN (1/1). CLICK TO VIEW
GA3055 Gastric Cancer ADC Moderately differentiated adenocarcinoma of stomach CLICK TO VIEW
GA3102 Gastric Cancer ADC Poorly differentiated adenocarcinoma of stomach with hepatic metastases. Regional LN: LN of proximal lesser curvature (17/18), LN of distal lesser curvature (9/9), porta hepatic LN (1/1), LN of proximal greater curvature (0/8), LN of distal greater curvature (0/3), mesenteric LN (0/1). CLICK TO VIEW
GA3109 Gastric Cancer ADC Moderately differentiated adenocarcinoma of gastric antrum. The tumor forms irregular glandular or cribriform structures and has an infiltrative growth pattern. Regional LN: LN of proximal lesser curvature (0/9), LN of distal lesser curvature (0/7), LN of proximal greater curvature (1/3), LN of distal greater curvature (4/7), common hepatic arterial LN (1/1). CLICK TO VIEW
GA3121 Gastric Cancer ADC Poorly differentiated adenocarcinoma from juncture of stomach and esophagus. CLICK TO VIEW
GA3155 Gastric Cancer ADC Moderately differentiated adenocarcinoma of stomach. The tumor forms glandular or cribriform structures and has an infiltrative growth pattern. Regional LN: LN of proximal greater curvature (0/2), LN of distal greater curvature (0/5), LN of proximal lesser curvature (5/8), LN of distal lesser curvature (3/7). CLICK TO VIEW
GA3158 Gastric Cancer ADC, mucinous Mucinous adenocarcinoma, infiltrating through gastric wall and duodenal wall . Twenty-four of forty-one lymph nodes involved by metastatic carcinoma (24/41). IHC results: TS(-), b-tubulin(100%+~++), Ki67TP(-), ERCC-1(-), cMet(-), TopoIIa(20%++), CerbB2(-). CLICK TO VIEW
GA3236 Gastric Cancer ADC Poorly to moderately differentiated adenocarcinoma of antrum of stomach, infiltrating to submucosa. Seven of seventeen lymph nodes involved by metastatic carcinoma (7/17). CLICK TO VIEW
GA3341 Gastric Cancer ADC Residual stomach: poorly differentiated adenocarcinoma, infiltrating to serosa. Six of sixteen lymph nodes involved by metastatic carcinoma (6/16). CLICK TO VIEW
GA6200 Gastric Cancer ADC Poorly differentiated adenocarcinoma of stomach, infiltrating to serosa. All lymph nodes are benign (0/15) CLICK TO VIEW
GA6201 Gastric Cancer ADC Poorly differentiated adenocarcinoma of gastric lesser curvature, infiltrating subserosa. Four of twenty lymph nodes involved by metastatic carcinoma (4/20). CLICK TO VIEW
GA6202 Gastric Cancer ADC Poorly differentiated adenocarcinoma of stomach, infiltrating subserosa. Two of thirty lymph nodes involved by metastatic carcinoma (2/30). CLICK TO VIEW
GA6203 Gastric Cancer ADC Poorly differentiated adenocarcinoma of gastric body, infiltrating out of serosa. Four of sixteen lymph nodes involved by metastatic carcinoma (4/16). CLICK TO VIEW
GA6207 Gastric Cancer N/A N/A CLICK TO VIEW
GA6208 Gastric Cancer ADC Tubular adenocarcinoma of stomach, grade II-III, infiltrating to subserosa. Two of thirteen lymph nodes involved by metastatic carcinoma. CLICK TO VIEW
GA6209 Gastric Cancer ADC Poorly differentiated adenocarcinoma of stomach, infiltrating to serosa. One out of six lymph nodes showed metastatic adenocarcinoma (1/6). CLICK TO VIEW
GA6210 Gastric Cancer ADC Poorly differentiated adenocarcinoma of gastric lesser curvature, infiltrating to serosa. All lymph nodes are benign (0/21). CLICK TO VIEW
GA6211 Gastric Cancer ADC Moderately differentiated tubular adenocarcinoma. Tumor invaded to subserosal liver. Fourteen of thirty-two lymph nodes involved by metastatic carcinoma(14/32). CLICK TO VIEW
GA6212 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma of pylorus, infiltrating to serosa. All lymph nodes are benign (0/52). CLICK TO VIEW
GA6214 Gastric Cancer ADC Tubular adenocarcinoma of fundus of stomach, grade II-III. Tumor invaded to serosa, all lymph nodes are benign (0/24). CLICK TO VIEW
GA6215 Gastric Cancer ADC Adenocarcinoma of stomach, grade II. Tumor cells show glandular structure, atypia and invade to subserosal fibrofatty tissue. Five of twenty-two lymph nodes involved by metastatic carcinoma. CLICK TO VIEW
GA6239 Gastric Cancer ADC Gastric angle: mucinous adenocarcinoma, poorly differentiated, infiltrating to serosa. Twenty-one out of thirty-one lymph nodes showed metastatic adenocarcinoma (21/31). CLICK TO VIEW
GA6240 Gastric Cancer N/A N/A CLICK TO VIEW
GA6273 Gastric Cancer ADC Antrum of stomach: poorly differentiated adenocarcinoma. Eight of thirty-two lymph nodes involved by malignant carcinoma (8/32) CLICK TO VIEW
GA6275 Gastric Cancer ADC Lesser curvature side of stomach: tubular adenocarcinoma, grade II, with mucinous component, infiltrating to serosa. All lymph nodes are benign (0/19). CLICK TO VIEW
GA6276 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma of stomach, infiltrating to subserosal fibrous tissue. All lymph nodes are benign (0/23). CLICK TO VIEW
GA6305 Gastric Cancer ADC Lesser curvature of stomach: poorly differentiated adenocarcinoma, with mucinous adenocarcinoma component CLICK TO VIEW
GA6806 Gastric Cancer NA Gastric adenocarcinoma. CLICK TO VIEW
GA6807 Gastric Cancer ADC Poorly differentiated adenocarcinoma, HER2 (2+) CLICK TO VIEW
GA6810 Gastric Cancer ADC Moderately differentiated adenocarcinoma, HER2(2+) CLICK TO VIEW
GA6811 Gastric Cancer ADC Moderately differentiated adenocarcinoma CLICK TO VIEW
GA6812 Gastric Cancer NA NA CLICK TO VIEW
GA6815 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma CLICK TO VIEW
GA6816 Gastric Cancer NA NA CLICK TO VIEW
GA6819 Gastric Cancer ADC Moderately differentiated adenocarcinoma, HER2(-) CLICK TO VIEW
GA6820 Gastric Cancer ADC Moderately differentiated adenocarcinoma. HER2 (2+) CLICK TO VIEW
GA6821 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma. HER2 (2+) CLICK TO VIEW
GA6822 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma. HER2 (2+) CLICK TO VIEW
GA6823 Gastric Cancer N/A N/A CLICK TO VIEW
GA6825 Gastric Cancer Adenocarcinoma NA CLICK TO VIEW
GA6828 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma CLICK TO VIEW
GA6829 Gastric Cancer ADC Poorly differentiated adenocarcinoma CLICK TO VIEW
GA6830 Gastric Cancer ADC Moderately differentiated adenocarcinoma CLICK TO VIEW
GA6831 Gastric Cancer ADC Intramucosal adenocarcinoma CLICK TO VIEW
GA6832 Gastric Cancer ADC Moderately differentiated adenocarcinoma CLICK TO VIEW
GA6833 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma CLICK TO VIEW
GA6834 Gastric Cancer ADC Poorly differentiated adenocarcinoma CLICK TO VIEW
GA6836 Gastric Cancer ADC Well differentiated adenocarcinoma CLICK TO VIEW
GA6839 Gastric Cancer ADC Poorly differentiated adenocarcinoma CLICK TO VIEW
GA6843 Gastric Cancer ADC Poorly differentiated adenocarcinoma CLICK TO VIEW
GA6844 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma CLICK TO VIEW
GA6846 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma CLICK TO VIEW
GA6864 Gastric Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
GA6865 Gastric Cancer ADC Moderately differentiated adenocarcinoma of fundus to antrum of stomach, infiltrating through gastric wall. sixteen of thirty-four lymph nodes involved by metastatic carcinoma (16/34). CLICK TO VIEW
GA6866 Gastric Cancer ADC Poorly differentiated adenocarcinoma, ulcerative type, infiltrating to serosa. IHC: CD44(+),Cmet(+),EGFR(-),HER2(1+),Ki-67(+25-50%), MMP7(-), P170(+), P27(-), P53(+>75%), TOPOII(+25-50%). CLICK TO VIEW
GA6869 Gastric Cancer ADC Gastric-esophageal junction: poorly differentiated adenocarcinoma, infiltrating to gastric serosa. 32 of 42 lymph nodes involved by metastatic carcinoma (32/42). CLICK TO VIEW
GA6871 Gastric Cancer ADC gastric adenocarcinoma, poorly differentiated CLICK TO VIEW
GA6873 Gastric Cancer ADC Gastric-esophageal junction: poorly differentiated adenocarcinoma, infiltrating through gastric wall. 4 of 39 lymph nodes involved by metastatic carcinoma (4/39). CLICK TO VIEW
GA6875 Gastric Cancer ADC Poorly differentiated adenocarcinoma of antrum of stomach, infiltrating to deep muscularis. No lymph nodes involved by metastatic carcinoma (0/19). CLICK TO VIEW
GA6876 Gastric Cancer ADC Gastric cardia: poorly differentiated adenocarcinoma, infiltrating through gastric wall. 10 of 14 lymph nodes involved by metastatic carcinoma (10/14). CLICK TO VIEW
GA6877 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma of antrum of stomach, infiltrating through gastric wall. No lymph nodes involved by metastatic carcinoma (0/39). CLICK TO VIEW
GA6878 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma of antrum of stomach, infiltrating through gastric wall. Two of sixty lymph nodes involved by metastatic carcinoma (2/60). CLICK TO VIEW
GA6881 Gastric Cancer ADC Moderately differentiated adenocarcinoma from juncture of stomach and esophagus, infiltrating through gastric wall. No lymph nodes involved by metastatic carcinoma (0/18). CLICK TO VIEW
GA6882 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma from juncture of stomach and esophagus, infiltrating through gastric wall to esophagus. Ten of thirty-six lymph nodes involved by metastatic carcinoma (10/36). CLICK TO VIEW
GA6885 Gastric Cancer ADC Poorly differentiated adenocarcinoma of antrum of stomach, infiltrating through gastric wall. One of twenty-one lymph nodes involved by metastatic carcinoma (1/21). CLICK TO VIEW
GA6889 Gastric Cancer ADC Poorly differentiated adenocarcinoma of antrum of stomach, infiltrating to serosa. One of twenty-six lymph nodes involved by metastatic carcinoma (1/26). CLICK TO VIEW
GA6891 Gastric Cancer ADC Moderately to poorly differentiated adenocarcinoma of antrum of stomach, infiltrating through gastric wall. One of five lymph nodes involved by metastatic carcinoma (1/5). CLICK TO VIEW
GA6894 Gastric Cancer ADC Poorly differentiated adenocarcinoma of antrum of stomach (Lauren typing: mixed type), infiltrating through gastric wall. Two of thirty lymph nodes involved by metastatic carcinoma (2/30). CLICK TO VIEW
GA6897 Gastric Cancer ADC Lesser curvature of stomach: poorly differentiated adenocarcinoma, infiltrating through gastric wall. CLICK TO VIEW
GA6898 Gastric Cancer NA NA for clinical diagnosis info. CLICK TO VIEW

Sorry, no posts matched your criteria.

Create Account to View All Model Data

Already Registered? Login